Recent news highlights include quarterly earnings reports showing losses with revenue performance, publication of pooled phase 3 data for Emrosi in rosacea, and increased payer coverage supporting prescription demand.

• Journey Medical reported Q3 2025 loss and revenue performance below estimates, reflecting ongoing challenges in profitability and growth [N2][N3].
• The company released pooled phase 3 clinical data for Emrosi in rosacea, supporting its efficacy profile [N7].
• Payer coverage for Emrosi increased to 65% of commercial lives, supporting growing prescription demand [N8].
• Journey Medical reported Q2 2025 loss but revenue performance above estimates, indicating mixed quarterly results [N8].
• The company’s Emrosi product was featured on a national TV segment highlighting its FDA-approved status for rosacea treatment [N8].
• Journey Medical joined the Russell 2000 and Russell 3000 indexes in June 2025, reflecting its market presence [S1].
• After-hours earnings report for March 25, 2026, included Journey Medical among other companies reporting financial results [N1].

Journey Medical’s focused portfolio of dermatology products with strong patent protection and FDA approvals positions it to address significant patient populations in rosacea, acne, and hyperhidrosis. The launch and commercialization of Emrosi, supported by positive phase 3 data and increasing payer coverage, may drive prescription growth. The company’s strategy to expand its product portfolio through acquisitions and licensing, combined with its commercial capabilities, could enhance revenue streams. Continued investment in lifecycle management and new product launches, such as the planned anti-itch product, may support long-term value creation.

Journey Medical faces challenges including ongoing net losses and the need to achieve sustainable profitability. The dermatology pharmaceutical market is competitive with multiple established therapies, which may limit market share gains. Regulatory, reimbursement, and patent risks could impact product commercialization. The company’s reliance on a limited number of products for revenue and the need for successful execution of growth strategies, including acquisitions and new product launches, present execution risks. Market acceptance and payer coverage expansion are critical to support prescription demand and financial performance.

Journey Medical’s moat is supported by its portfolio of FDA-approved dermatological products protected by multiple Orange Book-listed patents extending through 2030 to 2039. Its proprietary formulations, such as Emrosi’s extended-release minocycline technology and topical MST™ technology for Amzeeq and Zilxi, provide differentiation. The company’s commercial infrastructure and established relationships with healthcare providers support product promotion and lifecycle management. Additionally, payer coverage expansion for key products like Emrosi enhances market access. However, the company operates in competitive therapeutic areas with established alternatives, requiring ongoing innovation and commercialization efforts to maintain market position.

• Commercial Execution Risk: The company’s ability to grow revenue depends on successful marketing and sales of its existing products and new product launches, which may be affected by competition and market acceptance.
• Regulatory and Patent Risks: Changes in FDA regulations, patent challenges, or loss of exclusivity could impact product availability and competitive positioning.
• Financial Risk: The company reported net losses and requires sufficient liquidity and capital to fund operations, product development, and commercialization efforts.
• Market and Reimbursement Risk: Expansion of payer coverage and reimbursement levels are critical for prescription demand; unfavorable changes could adversely affect sales.

• Journey Medical Corp is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription drugs for dermatological conditions in the U.S.
• The company markets eight FDA-approved prescription drugs including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend.
• Emrosi, approved by the FDA in November 2024 for inflammatory lesions of rosacea in adults, began sales promotion in April 2025.
• Qbrexza is a topical medicated cloth for primary axillary hyperhidrosis, acquired and launched in May 2021.
• Accutane is an oral isotretinoin drug for severe recalcitrant nodular acne, licensed in July 2020 and launched in March 2021.
• Amzeeq and Zilxi are topical minocycline foams for acne and rosacea, respectively, both launched in January 2022.
• The company is a controlled subsidiary of Fortress Biotech, Inc.
• Journey Medical reported full-year 2025 revenue of $61.858 million and a net loss of $11.431 million, with basic and diluted EPS of -$0.47 per share as of December 31, 2025.
• As of December 31, 2025, the company had $24.09 million in cash and cash equivalents, current assets of $66.873 million, current liabilities of $37.442 million, a current ratio of 1.79, and a cash ratio of 0.64.
• The company’s strategy includes commercial execution of existing products, lifecycle management, out-licensing, and growth through acquisitions and licensing.
• Emrosi uses a multiple unit pellet system technology combining immediate and extended release minocycline and holds patents extending through January 2039.
• The rosacea market had over 1.5 million prescriptions in 2025; topical rosacea prescriptions exceeded 4.7 million in 2025.
• Qbrexza has eight Orange Book-listed patents extending through February 2033; Amzeeq has 12 patents through September 2037; Zilxi has nine patents through October 2030.
• The company plans to launch a non-steroidal, antihistamine-free anti-itch product in the first half of 2026.
• Journey Medical joined the Russell 2000 and Russell 3000 indexes in June 2025.
• Recent news includes reports on quarterly earnings, pooled phase 3 data for Emrosi, and increased payer coverage for Emrosi to 65% of commercial lives, supporting prescription demand.